Genome-wide screen for differentially methylated long noncoding RNAs identifies Esrp2 and lncRNA Esrp2-as regulated by enhancer DNA methylation with prognostic relevance for human breast cancer

Oncogene

Volumn 36, Issue 46, 2017, Pages 6446-6461

  Heilmann, K ^a   Toth, R ^a   Bossmann, C ^a   Klimo, K ^a   Plass, C ^a   Gerhauser, C ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; DECITABINE; DNA; EPITHELIAL SPLICING REGULATORY PROTEIN 2; ESRP2 AS PROTEIN; LONG UNTRANSLATED RNA; LUCIFERASE; UNCLASSIFIED DRUG; UNTRANSLATED RNA; ESRP2 PROTEIN, MOUSE; RNA BINDING PROTEIN; VIRUS T ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER TISSUE; CELL MOTILITY; CELL PROLIFERATION; CONTROLLED STUDY; DNA METHYLATION; ENHANCER REGION; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; GENOME-WIDE ASSOCIATION STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; LUCIFERASE ASSAY; MAMMARY GLAND; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; RECEPTOR UPREGULATION; REPORTER GENE; TISSUE SPECIFICITY; TRANSCRIPTION REGULATION; TUMOR XENOGRAFT; 3T3-L1 CELL LINE; ANIMAL; BREAST TUMOR; DISEASE MODEL; EXPERIMENTAL MAMMARY NEOPLASM; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PROCEDURES; PROGNOSIS; SURVIVAL ANALYSIS; TRANSGENIC MOUSE; TUMOR CELL LINE; WESTERN BLOTTING;

3T3-L1 CELLS; ANIMALS; ANTIGENS, VIRAL, TUMOR; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, TRANSGENIC; PROGNOSIS; RNA, LONG NONCODING; RNA-BINDING PROTEINS; SURVIVAL ANALYSIS;

EID: 85034427480     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2017.246     Document Type: Article

References (119)

1. Sahu A, Singhal U, Chinnaiyan AM. Long noncoding RNAs in cancer: from function to translation. Trends Cancer 2015; 1: 93-109.
2. Geisler S, Coller J. RNA in unexpected places: long non-coding RNA functions in diverse cellular contexts. Nat Rev Mol Cell Biol 2013; 14: 699-712.
3. Guil S, Esteller M. Cis-acting noncoding RNAs: friends and foes. Nat Struct Mol Biol 2012; 19: 1068-1075.
4. Kallen AN, Zhou XB, Xu J, Qiao C, Ma J, Yan L et al. The imprinted H19 lncRNA antagonizes let-7 microRNAs. Mol Cell 2013; 52: 101-112.
5. Pelechano V, Steinmetz LM. Gene regulation by antisense transcription. Nat Rev Genet 2013; 14: 880-893.
6. Hu X, Feng Y, Zhang D, Zhao Sihai D, Hu Z, Greshock J et al. A functional genomic approach identifies fal1 as an oncogenic long noncoding RNA that associates with BMI1 and Represses p21 Expression in Cancer. Cancer Cell 2014; 26: 344-357.
7. Tsai MC, Manor O, Wan Y, Mosammaparast N, Wang JK, Lan F et al. Long noncoding RNA as modular scaffold of histone modification complexes. Science 2010; 329: 689-693.
8. Arab K, Park YJ, Lindroth AM, Schafer A, Oakes C, Weichenhan D et al. Long noncoding RNA TARID directs demethylation and activation of the tumor suppressor TCF21 via GADD45A. Mol Cell 2014; 55: 604-614.
9. Lee C, Kikyo N. Strategies to identify long noncoding RNAs involved in gene regulation. Cell Biosci 2012; 2: 37.
10. Qin D, Xu C. Study strategies for long non-coding RNAs and their roles in regulating gene expression. Cell Mol Biol Lett 2015; 20: 323-349.
11. Guttman M, Amit I, Garber M, French C, Lin MF, Feldser D et al. Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature 2009; 458: 223-227.
12. Warzecha CC, Jiang P, Amirikian K, Dittmar KA, Lu H, Shen S et al. An ESRPregulated splicing programme is abrogated during the epithelial-mesenchymal transition. EMBO J 2010; 29: 3286-3300.
13. Horiguchi K, Sakamoto K, Koinuma D, Semba K, Inoue A, Inoue S et al. TGF-beta drives epithelial-mesenchymal transition through deltaEF1-mediated downregulation of ESRP. Oncogene 2012; 31: 3190-3201.
14. Shapiro IM, Cheng AW, Flytzanis NC, Balsamo M, Condeelis JS, Oktay MH et al. An EMT-driven alternative splicing program occurs in human breast cancer and modulates cellular phenotype. PLoS Genet 2011; 7: e1002218.
15. Bonnans C, Chou J, Werb Z. Remodelling the extracellular matrix in development and disease. Nat Rev Mol Cell Biol 2014; 15: 786-801.
16. De Craene B, Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer 2013; 13: 97-110.
17. Gottgens EL, Span PN, Zegers MM. Roles and regulation of epithelial splicing regulatory proteins 1 and 2 in Epithelial-Mesenchymal Transition. Int Rev Cell Mol Biol 2016; 327: 163-194.
18. Pradella D, Naro C, Sette C, Ghigna C. EMT and stemness: flexible processes tuned by alternative splicing in development and cancer progression. Mol Cancer 2017; 16: 8.
19. Hayakawa A, Saitoh M, Miyazawa K. Dual Roles for Epithelial Splicing Regulatory Proteins 1 (ESRP1) and 2 (ESRP2) in Cancer Progression. Adv Exp Med Biol 2016; 925: 33-40.
20. Green JE, Shibata MA, Yoshidome K, Liu ML, Jorcyk C, Anver MR et al. The C3(1)/SV40 T-antigen transgenic mouse model of mammary cancer: ductal epithelial cell targeting withmultistage progression to carcinoma. Oncogene 2000; 19: 1020-1027.
21. Maroulakou IG, Anver M, Garrett L, Green JE. Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. Proc Natl Acad Sci U S A 1994; 91: 11236-11240.
22. Gebhard C, Schwarzfischer L, Pham TH, Schilling E, Klug M, Andreesen R et al. Genome-wide profiling of CpG methylation identifies novel targets of aberrant hypermethylation in myeloid leukemia. Cancer Res 2006; 66: 6118-6128.
23. Holzer RG, MacDougall C, Cortright G, Atwood K, Green JE, Jorcyk CL. Development and Characterization of a Progressive Series of Mammary Adenocarcinoma Cell Lines Derived from the C3(1)/SV40 Large T-antigen Transgenic Mouse Model. Breast Cancer Res Treat 2003; 77: 65-76.
24. Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 2007; 8: R76.
25. Li AM, Tian AX, Zhang RX, Ge J, Sun X, Cao XC. Protocadherin-7 induces bone metastasis of breast cancer. Biochem Biophys Res Commun 2013; 436: 486-490.
26. Iwakiri M, Mizukami K, Ikonomovic MD, Ishikawa M, Abrahamson EE, DeKosky ST et al. An immunohistochemical study of GABA A receptor gamma subunits in Alzheimer's disease hippocampus: relationship to neurofibrillary tangle progression. Neuropathology 2009; 29: 263-269.
27. Xu Z, Pei L, Wang L, Zhang F, Hu X, Gui Y. Snail1-dependent transcriptional repression of Cezanne2 in hepatocellular carcinoma. Oncogene 2014; 33: 2836-2845.
28. Bai Y, Fang N, Gu T, Kang Y, Wu J, Yang D et al. HOXA11 gene is hypermethylation and aberrant expression in gastric cancer. Cancer Cell Int 2014; 14: 79.
29. Hwang JA, Lee BB, Kim Y, Park SE, Heo K, Hong SH et al. HOXA11 hypermethylation is associated with progression of non-small cell lung cancer. Oncotarget 2013; 4: 2317-2325.
30. Reaves DK, Fagan-Solis KD, Dunphy K, Oliver SD, Scott DW, Fleming JM. The role of lipolysis stimulated lipoprotein receptor in breast cancer and directing breast cancer cell behavior. PLoS ONE 2014; 9: e91747.
31. Zhao J, Ohsumi TK, Kung JT, Ogawa Y, Grau DJ, Sarma K et al. Genome-wide identification of polycomb-associated RNAs by RIP-seq. Mol Cell 2010; 40: 939-953.
32. Forrest AR, Kawaji H, Rehli M, Baillie JK, de Hoon MJ, Haberle V et al. A promoterlevel mammalian expression atlas. Nature 2014; 507: 462-470.
33. Lizio M, Harshbarger J, Shimoji H, Severin J, Kasukawa T, Sahin S et al. Gateways to the FANTOM5 promoter level mammalian expression atlas. Genome Biol 2015; 16: 22.
34. Robertson G, Hirst M, Bainbridge M, Bilenky M, Zhao Y, Zeng T et al. Genomewide profiles of STAT1 DNA association using chromatin immunoprecipitation and massively parallel sequencing. Nat Methods 2007; 4: 651-657.
35. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102: 15545-15550.
36. Naba A, Clauser KR, Ding H, Whittaker CA, Carr SA, Hynes RO. The extracellular matrix: Tools and insights for the "omics" era. Matrix Biol 2016; 49: 10-24.
37. Bashir M, Damineni S, Mukherjee G, Kondaiah P. Activin-A signaling promotes epithelial-mesenchymal transition, invasion, and metastatic growth of breast cancer. Npj Breast Cancer 2015; 1: 15007.
38. Yang F, Xu J, Tang L, Guan X. Breast cancer stem cell: the roles and therapeutic implications. Cell Mol Life Sci 2017; 74: 951-966.
39. Rosenbloom KR, Sloan CA, Malladi VS, Dreszer TR, Learned K, Kirkup VM et al. ENCODE data in the UCSC Genome Browser: year 5 update. Nucleic Acids Res 2013; 41: D56-D63.
40. Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, Zahler AM et al. The human genome browser at UCSC. Genome Res 2002; 12: 996-1006.
41. Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat 2010; 123: 725-731.
42. Li Y, Zhang Y, Li S, Lu J, Chen J, Wang Y et al. Genome-wide DNA methylome analysis reveals epigenetically dysregulated non-coding RNAs in human breast cancer. Sci Rep 2015; 5: 8790.
43. Bennett CN, Green JE. Genomic analyses as a guide to target identification and preclinical testing of mouse models of breast cancer. Toxicol Pathol 2010; 38: 88-95.
44. Bennett CN, Green JE. Unlocking the power of cross-species genomic analyses: identification of evolutionarily conserved breast cancer networks and validation of preclinical models. Breast Cancer Res 2008; 10: 213.
45. Deeb KK, Michalowska AM, Yoon CY, Krummey SM, Hoenerhoff MJ, Kavanaugh C et al. Identification of an integrated SV40 T/t-antigen cancer signature in aggressive human breast, prostate, and lung carcinomas with poor prognosis. Cancer Res 2007; 67: 8065-8080.
46. Zhu M, Yi M, Kim CH, Deng C, Li Y, Medina D et al. Integrated miRNA and mRNA expression profiling of mouse mammary tumor models identifies miRNA signatures associated with mammary tumor lineage. Genome Biol 2011; 12: R77.
47. Bertucci F, Finetti P, Birnbaum D. Basal breast cancer: a complex and deadly molecular subtype. Curr Mol Med 2012; 12: 96-110.
48. Ades F, Zardavas D, Bozovic-Spasojevic I, Pugliano L, Fumagalli D, de Azambuja E et al. Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. J Clin Oncol 2014; 32: 2794-2803.
49. Grote P, Wittler L, Hendrix D, Koch F, Wahrisch S, Beisaw A et al. The tissuespecific lncRNA Fendrr is an essential regulator of heart and body wall development in the mouse. Dev Cell 2013; 24: 206-214.
50. Yu H, Lindsay J, Feng ZP, Frankenberg S, Hu Y, Carone D et al. Evolution of coding and non-coding genes in HOX clusters of a marsupial. BMC Genomics 2012; 13: 251.
51. Chau YM, Pando S, Taylor HS. HOXA11 silencing and endogenous HOXA11 antisense ribonucleic acid in the uterine endometrium. J Clin Endocrinol Metab 2002; 87: 2674-2680.
52. Yarmishyn A, Batagov A, Tan J, Sundaram G, Sampath P, Kuznetsov V et al. HOXD-AS1 is a novel lncRNA encoded in HOXD cluster and a marker of neuroblastoma progression revealed via integrative analysis of noncoding transcriptome. BMC Genomics 2014; 15: S7.
53. Abate-Shen C. Deregulated homeobox gene expression in cancer: cause or consequence? Nat Rev Cancer 2002; 2: 777-785.
54. Tommasi S, Karm DL, Wu X, Yen Y, Pfeifer GP. Methylation of homeobox genes is a frequent and early epigenetic event in breast cancer. Breast Cancer Res 2009; 11: R14.
55. Faryna M, Konermann C, Aulmann S, Bermejo JL, Brugger M, Diederichs S et al. Genome-wide methylation screen in low-grade breast cancer identifies novel epigenetically altered genes as potential biomarkers for tumor diagnosis. FASEB J 2012; 26: 4937-4950.
56. Gal-Yam EN, Egger G, Iniguez L, Holster H, Einarsson S, Zhang X et al. Frequent switching of Polycomb repressive marks and DNA hypermethylation in the PC3 prostate cancer cell line. Proc Natl Acad Sci USA 2008; 105: 12979-12984.
57. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 2003; 34: 267-273.
58. Meissner A, Mikkelsen TS, Gu H, Wernig M, Hanna J, Sivachenko A et al. Genomescale DNA methylation maps of pluripotent and differentiated cells. Nature 2008; 454: 766-770.
59. Mikkelsen TS, Ku M, Jaffe DB, Issac B, Lieberman E, Giannoukos G et al. Genomewide maps of chromatin state in pluripotent and lineage-committed cells. Nature 2007; 448: 553-560.
60. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 2008; 40: 499-507.
61. Nikolsky Y, Sviridov E, Yao J, Dosymbekov D, Ustyansky V, Kaznacheev V et al. Genome-wide functional synergy between amplified and mutated genes in human breast cancer. Cancer Res 2008; 68: 9532-9540.
62. Wang W, Huper G, Guo Y, Murphy SK, Olson JA Jr, Marks JR. Analysis of methylation-sensitive transcriptome identifies GADD45a as a frequently methylated gene in breast cancer. Oncogene 2005; 24: 2705-2714.
63. Jaeger J, Koczan D, Thiesen HJ, Ibrahim SM, Gross G, Spang R et al. Gene expression signatures for tumor progression, tumor subtype, and tumor thickness in laser-microdissected melanoma tissues. Clin Cancer Res 2007; 13: 806-815.
64. Bock C, Beerman I, Lien WH, Smith ZD, Gu H, Boyle P et al. DNA methylation dynamics during in vivo differentiation of blood and skin stem cells. Mol Cell 2012; 47: 633-647.
65. Aran D, Sabato S, Hellman A. DNA methylation of distal regulatory sites characterizes dysregulation of cancer genes. Genome Biol 2013; 14: R21.
66. Warzecha CC, Carstens RP. Complex changes in alternative pre-mRNA splicing play a central role in the epithelial-to-mesenchymal transition (EMT). Semin Cancer Biol 2012; 22: 417-427.
67. Gumireddy K, Li A, Yan J, Setoyama T, Johannes GJ, Orom UA et al. Identification of a long non-coding RNA-associated RNP complex regulating metastasis at the translational step. EMBO J 2013; 32: 2672-2684.
68. Yoon JH, Abdelmohsen K, Srikantan S, Yang X, Martindale JL, De S et al. LincRNAp21 suppresses target mRNA translation. Mol Cell 2012; 47: 648-655.
69. Hu G, Lou Z, Gupta M. The long non-coding RNA GAS5 cooperates with the eukaryotic translation initiation factor 4E to regulate c-Myc translation. PLoS One 2014; 9: e107016.
70. Carrieri C, Cimatti L, Biagioli M, Beugnet A, Zucchelli S, Fedele S et al. Long noncoding antisense RNA controls Uchl1 translation through an embedded SINEB2 repeat. Nature 2012; 491: 454-457.
71. Tseng Y-Y, Bagchi A. The PVT1-MYC duet in cancer. Mol Cell Oncol 2015; 2: e974467.
72. Tseng YY, Moriarity BS, Gong W, Akiyama R, Tiwari A, Kawakami H et al. PVT1 dependence in cancer with MYC copy-number increase. Nature 2014; 512: 82-86.
73. Hynes RO, Naba A. Overview of the matrisome-an inventory of extracellular matrix constituents and functions. Cold Spring Harb Perspect Biol 2012; 4: a004903.
74. Asch-Kendrick R, Cimino-Mathews A. The role of GATA3 in breast carcinomas: a review. Hum Pathol 2016; 48: 37-47.
75. Batts TD, Machado HL, Zhang Y, Creighton CJ, Li Y, Rosen JM. Stem cell antigen-1 (sca-1) regulates mammary tumor development and cell migration. PLoS One 2011; 6: e27841.
76. Blaas L, Pucci F, Messal HA, Andersson AB, Josue Ruiz E, Gerling M et al. Lgr6 labels a rare population of mammary gland progenitor cells that are able to originate luminal mammary tumours. Nat Cell Biol 2016; 18: 1346-1356.
77. Wang D, Cai C, Dong X, Yu QC, Zhang XO, Yang L et al. Identification of multipotent mammary stem cells by protein C receptor expression. Nature 2015; 517: 81-84.
78. Drake LE, Macleod KF. Tumour suppressor gene function in carcinomaassociated fibroblasts: from tumour cells via EMT and back again? J Pathol 2014; 232: 283-288.
79. Visvader JE, Stingl J. Mammary stem cells and the differentiation hierarchy: current status and perspectives. Genes Dev 2014; 28: 1143-1158.
80. Walrath JC, Hawes JJ, Van Dyke T, Reilly KM. Genetically engineered mouse models in cancer research. Adv Cancer Res 2010; 106: 113-164.
81. Kersten K, de Visser KE, van Miltenburg MH, Jonkers J. Genetically engineered mouse models in oncology research and cancer medicine. EMBO Mol Med 2017; 9: 137-153.
82. Di Palma T, Filippone MG, Pierantoni GM, Fusco A, Soddu S, Zannini M. Pax8 has a critical role in epithelial cell survival and proliferation. Cell Death Dis 2013; 4: e729.
83. Huang HY, Wu WR, Wang YH, Wang JW, Fang FM, Tsai JW et al. ASS1 as a novel tumor suppressor gene in myxofibrosarcomas: aberrant loss via epigenetic DNA methylation confers aggressive phenotypes, negative prognostic impact, and therapeutic relevance. Clin Cancer Res 2013; 19: 2861-2872.
84. Minden A. The pak4 protein kinase in breast cancer. ISRN Oncol 2012; 2012: 694201.
85. Punj V, Matta H, Chaudhary PM. X-linked ectodermal dysplasia receptor is downregulated in breast cancer via promoter methylation. Clin Cancer Res 2010; 16: 1140-1148.
86. Ishii H, Saitoh M, Sakamoto K, Kondo T, Katoh R, Tanaka S et al. Epithelial splicing regulatory proteins 1 (ESRP1) and 2 (ESRP2) suppress cancer cell motility via different mechanisms. J Biol Chem 2014; 289: 27386-27399.
87. Deloria AJ, Hoflmayer D, Kienzl P, Lopatecka J, Sampl S, Klimpfinger M et al. Epithelial splicing regulatory protein 1 and 2 paralogues correlate with splice signatures and favorable outcome in human colorectal cancer. Oncotarget 2016; 7: 73800-73816.
88. Mizutani A, Koinuma D, Seimiya H, Miyazono K. The Arkadia-ESRP2 axis suppresses tumor progression: analyses in clear-cell renal cell carcinoma. Oncogene 2016; 35: 3514-3523.
89. Johnsson P, Lipovich L, Grander D, Morris KV. Evolutionary conservation of long non-coding RNAs; sequence, structure, function. Biochim Biophys Acta 2014; 1840: 1063-1071.
90. Diederichs S. The four dimensions of noncoding RNA conservation. Trends Genet 2014; 30: 121-123.
91. Sun H, Chen J, Qian W, Kang J, Wang J, Jiang L et al. Integrated long noncoding RNA analyses identify novel regulators of epithelial-mesenchymal transition in the mouse model of pulmonary fibrosis. J Cell Mol Med 2016; 20: 1234-1246.
92. Sonnet M, Baer C, Rehli M, Weichenhan D, Plass C. Enrichment of methylated DNA by methyl-CpG immunoprecipitation. Methods Mol Biol 2013; 971: 201-212.
93. Schilling E, Rehli M. Global, comparative analysis of tissue-specific promoter CpG methylation. Genomics 2007; 90: 314-323.
94. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009; 25: 1754-1760.
95. Yao Y, Li H, Gu Y, Davidson NE, Zhou Q. Inhibition of SIRT1 deacetylase suppresses estrogen receptor signaling. Carcinogenesis 2010; 31: 382-387.
96. Lienhard M, Grimm C, Morkel M, Herwig R, Chavez L. MEDIPS: genome-wide differential coverage analysis of sequencing data derived from DNA enrichment experiments. Bioinformatics 2014; 30: 284-286.
97. Heinz S, Benner C, Spann N, Bertolino E, Lin YC, Laslo P et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol Cell 2010; 38: 576-589.
98. Karolchik D, Hinrichs AS, Furey TS, Roskin KM, Sugnet CW, Haussler D et al. The UCSC Table Browser data retrieval tool. Nucleic Acids Res 2004; 32: D493-D496.
99. Quinlan AR. BEDTools: The Swiss-Army Tool for Genome Feature Analysis. Curr Protoc Bioinformatics 2014; 47: 11 12 11-11 12 34.
100. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using realtime quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402-408.
101. Ehrich M, Nelson MR, Stanssens P, Zabeau M, Liloglou T, Xinarianos G et al. Quantitative high-throughput analysis of DNA methylation patterns by basespecific cleavage and mass spectrometry. Proc Natl Acad Sci USA 2005; 102: 15785-15790.
102. Green H, Meuth M. An established pre-adipose cell line and its differentiation in culture. Cell 1974; 3: 127-133.
103. Morita S, Kojima T, Kitamura T. Plat-E: an efficient and stable system for transient packaging of retroviruses. Gene Ther 2000; 7: 1063-1066.
104. Deckers M, van Dinther M, Buijs J, Que I, Löwik C, van der Pluijm G et al. The tumor suppressor Smad4 is required for transforming growth factor β-induced epithelial to mesenchymal transition and bone metastasis of breast cancer Cells. Cancer Res 2006; 66: 2202-2209.
105. Darlington GJ. Liver cell lines. Methods Enzymol 1987; 151: 19-38.
106. Smalley MJ. Isolation, culture and analysis of mouse mammary epithelial cells. Methods Mol Biol 2010; 633: 139-170.
107. Jechlinger M, Podsypanina K, Varmus H. Regulation of transgenes in threedimensional cultures of primary mouse mammary cells demonstrates oncogene dependence and identifies cells that survive deinduction. Genes Dev 2009; 23: 1677-1688.
108. Baer C, Oakes CC, Ruppert AS, Claus R, Kim-Wanner S-Z, Mertens D et al. Epigenetic silencing of miR-708 enhances NF-κB signaling in chronic lymphocytic leukemia. Int J Cancer 2015; 137: 1352-1361.
109. Warzecha CC, Sato TK, Nabet B, Hogenesch JB, Carstens RP. ESRP1 and ESRP2 are epithelial cell-type-specific regulators of FGFR2 splicing. Mol Cell 2009; 33: 591-601.
110. Roring M, Herr R, Fiala GJ, Heilmann K, Braun S, Eisenhardt AE et al. Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling. EMBO J 2012; 31: 2629-2647.
111. Pappa G, Strathmann J, Lowinger M, Bartsch H, Gerhauser C. Quantitative combination effects between sulforaphane and 3,3′-diindolylmethane on proliferation of human colon cancer cells in vitro. Carcinogenesis 2007; 28: 1471-1477.
112. Martin M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnetjournal 2011; 17: 10-12 Available at http://journal.embnet.org/index.php/embnetjournal/article/view/200 (accessed on 29 December 2016).
113. Kim D, Langmead B, Salzberg SL. HISAT: a fast spliced aligner with low memory requirements. Nat Methods 2015; 12: 357-360.
114. Okonechnikov K, Conesa A, Garcia-Alcalde F. Qualimap 2: advanced multisample quality control for high-throughput sequencing data. Bioinformatics 2016; 32: 292-294.
115. Pertea M, Kim D, Pertea GM, Leek JT, Salzberg SL. Transcript-level expression analysis of RNA-seq experiments with HISAT, StringTie and Ballgown. Nat Protoc 2016; 11: 1650-1667.
116. Pertea M, Pertea GM, Antonescu CM, Chang TC, Mendell JT, Salzberg SL. StringTie enables improved reconstruction of a transcriptome from RNA-seq reads. Nat Biotechnol 2015; 33: 290-295.
117. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 2010; 26: 139-140.
118. McCarthy DJ, Chen Y, Smyth GK. Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation. Nucleic Acids Res 2012; 40: 4288-4297.
119. Anders S, Pyl PT, Huber W. HTSeq-a Python framework to work with highthroughput sequencing data. Bioinformatics 2015; 31: 166-169.